Alnylam Pharmaceuticals
ALNY
#554
Rank
HK$352.54 B
Marketcap
HK$2,658
Share price
0.23%
Change (1 day)
36.43%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of December 2025 : HK$32.64 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are HK$32.64 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2025)

Total liabilities by year

Year Total liabilities Change
2025-12-31HK$32.50 B0.32%
2024-12-31HK$32.39 B2.41%
2023-12-31HK$31.63 B9.29%
2022-12-31HK$28.94 B21.5%
2021-12-31HK$23.82 B28.53%
2020-12-31HK$18.53 B148.82%
2019-12-31HK$7.44 B248.64%
2018-12-31HK$2.13 B19.78%
2017-12-31HK$1.78 B-32.86%
2016-12-31HK$2.65 B181.42%
2015-12-31HK$0.94 B-15.09%
2014-12-31HK$1.11 B-4.54%
2013-12-31HK$1.16 B-2.1%
2012-12-31HK$1.18 B-6.57%
2011-12-31HK$1.27 B-30.39%
2010-12-31HK$1.82 B-22.25%
2009-12-31HK$2.35 B-13.64%
2008-12-31HK$2.72 B18.6%
2007-12-31HK$2.29 B660.61%
2006-12-31HK$0.30 B6.52%
2005-12-31HK$0.28 B82.74%
2004-12-31HK$0.15 B-67.66%
2003-12-31HK$0.47 B196.36%
2002-12-31HK$0.16 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Novartis
NVS
HK$503.29 B 1,441.72%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$516.01 B 1,480.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$72.69 B 122.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
HK$16.98 B-47.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
HK$45.31 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$5.39 B-83.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$256.60 B 686.04%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$8.13 B-75.07%๐Ÿ‡บ๐Ÿ‡ธ USA